stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Total debt
Alnylam Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $1.0B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.0B. Over the past ten years it has ranged from $30.0M (fiscal 2018) to $1.0B (fiscal 2024); the current reading is higher than 70% of that period. Alnylam Pharmaceuticals, Inc. ranks 13th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.0B | (1.64%) |
| FY2024 | $1.0B | 0.38% |
| FY2023 | $1.0B | 0.38% |
| FY2022 | $1.0B | 50.50% |
| FY2021 | $675.7M | 253.25% |
| FY2020 | $191.3M | (30.70%) |
| FY2019 | $276.0M | 820.00% |
| FY2018 | $30.0M | 0.00% |
| FY2017 | $30.0M | (80.00%) |
| FY2016 | $150.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $1.0B | 0.16% |
| Jun 2026 | $1.0B | 0.16% |
| Mar 2026 | $1.0B | 0.16% |
| Dec 2025 | $1.0B | (3.12%) |
| 38 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $5.6B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ALNY Alnylam Pharmaceuticals, Inc. | $1.0B |
| INSM Insmed, Inc. compare | $562.8M |
| ASND Ascendis Pharma A/S compare | $523.3M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| EXEL Exelixis, Inc. compare | $191.0M |
| INCY Incyte Corporation compare | $27.6M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement